N/A N=33 Young Adult Eating Habits
Eating Behavior · Eating Habit
Primary: Change in Brain Response From Baseline to 2-weeks Post High UPF or 2 Weeks no UPF Diet — 0.02; 0.13 arbitrary units
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=103 Effects of Probiotics in Immune System of Healthy Adults
Conditions Influencing Health Status
Primary: Gastrointestinal Tolerance After Probiotic Consumption. — 20; 20; 20; 20 participants
N/A N=365 Cell Phone Intervention in Young Adults
Obesity
Primary: Change in Body Weight — -0.99; -2.6; -1.7 kg
N/A N=316 Young Adult Hypertension Self-Management Clinical Trial
Hypertension · Blood Pressure · Lifestyle Risk Reduction
Primary: 24-hour Systolic Ambulatory Blood Pressure (mmHg) — 132.59; 133.01; 128.14; 130.69 mmHg
N/A N=44 The Effects of Added Sugar Intake on Brain Blood Flow and Hippocampal Function in Midlife Adults
Aging · Healthy Diet
Primary: Arterial Compliance (m^2 Kilopascal^-1) — 0.824; 0.772 m^2 kilopascal^-1
Phase 4 N=38 Live Attenuated Influenza Vaccine (LAIV) Versus Trivalent Inactivated Influenza Vaccine in Healthy Adults 18-49 Years
Influenza
Primary: Serum Antibody Responses — 11.76; 11.11; 47.03; 9.33 Titers — p=0.89
N/A N=105 Cell Mediated Immunity in Older Adults
Immunity to Influenza Vaccine
Primary: Cellular Immune Response — 0.239; 0.137; 0.243; 0.160 percentage of Stimulated cells
N/A N=44 Immune Function and Muscle Adaptations to Resistance Exercise in Older Adults
Sarcopenia · Aging · Immune Function
Primary: Change in Plasma Concentration of Antibodies to Pertussis Antigen (1 Week Post-vaccine) — 63.1; 63.2 units per ml — p=>0.05
Phase 1 N=4 Challenge Infection of Healthy Adult Volunteers With RSV A2
Upper Respiratory Tract Infections
Primary: Participants With Detectable RSV Shedding in Nasopharyngeal Wash — 2; 4 Participants
Phase 4 N=152 Age and Response to Flu Vaccines
Influenza · Influenza Immunisation
Primary: Magnitude of the Serum Antibody Response by Hemagglutination-inhibition (HAI) — 528 titer
N/A N=200 Urinalysis Results in Healthy Individuals
Asymptomatic Bacteriuria · Asymptomatic Pyuria
Primary: False Positive Urine — 6; 40 Participants
N/A N=36 Young Adult Congenital Heart Disease Physical Activity Lifestyle Study (YACHD-PALS)
Cardiovascular Disease Other · Physical Activity
Primary: Moderate to Vigorous Physical Activity (MVPA) — -0.7; 8.8 Average change in minutes per day — p=.023
Phase 1 N=12 A Study to Understand What the Body Does to the Study Medicine Called PF-07220060 When Taken by Healthy Adults
Healthy Participants
Primary: Percentage of Total Radiocarbon (14C) Excreted in Urine — 11.9; 20.7 Percentage of 14C in urine
Phase 3 N=302 Enhancing Fitness in Older Pre-diabetic Veterans
Impaired Glucose Tolerance · Obesity · Diabetes
Primary: Fasting Insulin — 10.26; 10.39 uIU/ml
N/A N=20 Healthy Patients & Effect of Antibiotics
Microbiota · Anti-bacterial Agents
Primary: Degree of Microbial Disruption: Number of Patients With Recovery of Bacterial Species Richness at 185 Days Post-antibiotics — 3; 3; 2; 3 Participants
N/A N=58 The Development of a Human Model of Respiratory Syncytial Virus Infection
Respiratory Syncytial Virus Infections · Respiratory Viral Infections
Primary: Host Response to RSV Challenge Measured as Change From Baseline of Chemical Mediators in Nasal Fluid — 23 Participants
N/A N=58 Almonds: Digestive Health and Immune Function of Adults and Children
Healthy
Primary: Gut Microbiota Community Composition — -.0116; -0.407; -0.161; -.0498 log (CFU)
Phase 1 N=12 A Study to Assess Two Forms of The Study Medicine (Ritlecitinib) in Healthy Adult Participants
Healthy Volunteers · Adult · Pharmacokinetics
Primary: Area Under the Plasma Concentration-Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf) of Ritlecitinib — 389.1; 398.3; 378.0; 387.8 nanogram*hour per…
Phase 3 N=126 Safety and Immunogenicity of a Cell Derived Subunit Trivalent Nonadjuvanted Influenza Study Vaccine in Adults Aged 18 Years and Above
Human Influenza
Primary: Percentage of Subjects With Single Radial Hemolysis (SRH) Areas ≥25mm2, Against Each of Three Vaccine Strains After Receiving One Dose of TIVc — 66; 41; 98; 84…
Phase 3 N=164 Calorie Restriction and Changes in Body Composition, Disease, Function, and Quality of Life in Older Adults
Obesity · Diabetes · Hypertension
Primary: Change in Abdominal Fat Mass — -192.6; -21.9; -275 Cubic cm
Phase 3 N=125 Safety and Immunogenicity of One Dose of Seasonal Trivalent Influenza Virus Vaccine (TIVf, Purified Surface Antigen, Inactivated, Egg Derived) in Adults, Aged 18 Years and Above
Human Influenza
Primary: Percentage of Subjects With Single Radial Hemolysis (SRH) Areas ≥25mm2, Against Each of Three Vaccine Strains After Receiving One Dose of TIVf — 17; 36; 95; 80…
Phase 1 N=12 A Single Dose Study To Test Two Pediatric Forms Of Ritlecitinib Compared With Adult Ritlecitinib In Healthy Adults
Healthy Participants
Primary: Area Under the Plasma Concentration-Time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) for Ritlecitinib — 361.1; 370.1; 385.1 nanograms*hours/milliliter…
N/A N=72 Physical Activity and Healthy Eating Among Young Adult Cancer Survivors
Physical Activity · Neoplasms · Cancer
Primary: Accrual Rate — 12 Participants per month
N/A N=24 The Monitoring Study
Type1diabetes
Primary: Percentage of Time Spent With Dexcom CGMG < 60 mg/dl — 1.32; 1.95; 1.05; 0.99 percentage of time
N/A N=48 Isometric Core Muscle Endurance in Healthy Active and Non-active Working Age Populations
Physical Endurance
Primary: Core Muscle Endurance — 530.5 seconds
Phase 2 N=341 Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-004)
Streptococcus Pneumoniae Infection · Pneumococcal Infections
Primary: Percentage of Adult Participants Experiencing ≥1 Adverse Event (AE) — 100.0; 100.0 Percentage of Participants
N/A N=34 RESP-FIT: Technology-Enhanced Self-Management in COPD
COPD
Primary: Intervention Feasibility (Number of Participants Who Adhered to Treatment) — 13; 14 Participants
N/A N=35 MAP to Health Pilot Study: A Physical Activity Intervention for Midlife Adults
Physical Inactivity
Primary: Meaning Salience — 5.61 score on a scale
N/A N=36 SARS-CoV-2 Human Challenge Characterisation Study
Covid19 · SARS-CoV Infection · Corona Virus Infection
Primary: Number of Unsolicited Adverse Events in Healthy Participants Challenged With Wild Type SARS-CoV-2 — 45 Unsolicited Adverse Events
Phase 3 N=3,086 A Study of Live Oral Cholera Vaccine, PXVX200 in Healthy Older Adults
Cholera
Primary: Seroconversion Rate at Day 11 — 90.4; 93.5 % of participants